Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models

Numerous combinations of signaling pathway blockades in association with tyrosine kinase inhibitor (TKI) treatment have been proposed for eradicating leukemic stem cells (LSCs) in chronic myeloid leukemia (CML), but none are currently clinically available. Because targeting protein kinase Cδ (PKCδ)...

Full description

Bibliographic Details
Main Authors: Fabien Muselli, Lucas Mourgues, Rita Morcos, Nathalie Rochet, Marielle Nebout, Agnès Guerci-Bresler, Douglas V Faller, Robert M William, Rana Mhaidly, Els Verhoeyen, Laurence Legros, Jean-François Peyron, Didier Mary
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
chronic myeloid leukemia
leukemic stem cells
tyrosine kinase inhibitors
apoptosis
BMI1
PKCδ
Online Access:https://www.mdpi.com/2072-6694/13/7/1693

Internet

https://www.mdpi.com/2072-6694/13/7/1693

Similar Items